Topics

Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows Promise

20:00 EDT 25 Mar 2020 | Cancer Networks

Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in this patient population.

Original Article: Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows Promise

NEXT ARTICLE

More From BioPortfolio on "Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows Promise"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...